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FGFs modulate diverse biological processes including embryonic
development. Secreted FGF-binding proteins (BPs) can release FGFs
from their local extracellular matrix storage, chaperone them to
their cognate receptors, and thus modulate FGF signaling. Here
we describe 2 chicken BP homologs (chBP) that show distinct
expression peaks at embryonic days E7.5 (chBP2) and E11.5
(chBP1), although their tissue distribution is similar (skin 
intestine>lung>heart, liver). Embryos were grown ex ovo to
monitor the phenotypic impact of a timed in vivo knockdown of
expression peaks by microinjection of specific siRNAs targeted to
either of the chBPs. Knockdown of peak expression of chBP2
caused embryonic lethality within <5 days. Surviving embryos
showed defective ventral wall closure indicative of altered dorso-
ventral patterning. This defect coincided with reduced expression
of HoxB7 but not HoxB8 that are involved in the control of
thoracic/abdominal segment morphology. Also, MAPK phospha-
tase 3, a negative regulator of FGF signaling, and sonic hedgehog
that can participate in feedback control of the FGF pathway were
reduced, reflecting altered FGF signaling. Knockdown of the chBP1
expression peak caused embryonic lethality within <3 days al-
though no distinct morphologic phenotype or pathways alter-
ations were apparent. We conclude that BPs play a significant role
in fine-tuning the complex FGF signaling network during distinct
phases of embryonic development.
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The FGF family consists of 18 distinct proteins that functionas receptor ligands and 4 transmembrane receptor tyrosine
kinases with multiple isoforms, thus creating a vast and
complex signaling network (1). FGF signaling plays a signifi-
cant role in development as well as in the maintenance of the
cardiovascular and nervous systems in the adult organism (2,
3). FGFs also have been shown to be essential in wound healing
(4) and to contribute to the growth and metastasis of cancer
cells (5). FGFs are expressed in embryonic and adult tissues,
and most of these proteins bind to heparan sulfate proteogly-
cans (HSPGs) in the ECM. This local storage provides addi-
tional control of growth factor activity in development and
disease (6). Two distinct mechanisms have been described by
which locally immobilized FGFs can be released from their
HSPG storage: One mechanism involves digestion of the sugar
backbone of HSPGs by heparanases or other glycosaminogly-
can-degrading enzymes. Another mechanism is the binding of
the extracellularly immobilized FGFs to secreted FGF-binding
proteins (BP) that serve as chaperones for FGFs. Wu et al. (7)
isolated the first secreted FGF BP (HBp17, BP1) from the
supernatants of human A431 carcinoma cells and found that
BP1 can bind to FGF1 and FGF2 in a reversible manner. Also,
BP1 can release FGFs from HSPGs, protect them from
degradation, and present them to their high-affinity receptors
in an active form (7–10)
Work from different laboratories has shown that BP1 interacts
at least with FGF1, -2, -7, -10, and -22 (9, 11). Heparan sulfate
and other heparinoids compete with BP1 binding to FGF2 (9),
and BP1 directly interacts with perlecan, an HSPG present in the
basement membrane (12). FGF binding to its transmembrane
receptor requires HSPGs to trigger receptor oligomerization and
signaling (reviewed in ref. 13), and BP1 can supplement this
HSPG function in FGF signaling when HSPGs have been
depleted from cells (14).
To date a majority of studies on BPs have focused on the
molecular mechanism of action of the protein, the control of
gene expression, and the function of BPs in malignancies (dis-
cussed in refs. 7, 10, 15, 16). None have addressed the possible
contributions of this protein family during embryonic develop-
ment. Because of the crucial roles of different FGFs in embry-
onic development (reviewed in refs. 1, 17), it is tempting to
speculate that BPs could provide an additional mechanism to
fine-tune the amplitude of FGF activity.
We used chick embryos as a model system and identified
chBP1, an orthologue of the human BP1, as well as another
family member, chBP2. In vitro assays suggest that the functional
properties of the chBP2 protein are indistinguishable from those
of the BP1 family. However, chBP2 expression was induced early
during embryogenesis, after embryonic day (E) 5, whereas
chBP1 induction too place mid-gestation, after E10. These
different expression profiles suggest distinct contributions of
these genes to physiologic development. Here we report the
impact of the knockdown of the expression peaks on embryo
survival as well as the specific phenotype observed after knock-
down of chBP2 and the dysregulation of genes associated with
FGF signaling.
Results and Discussion
Identification and Molecular Characterization of Chicken Orthologues
of Binding Protein. Database searches (TBLASTN) with the
human BP1 amino acid sequence revealed 2 distinct ESTs that
are predicted to code for homologous proteins in the chicken
(Gallus gallus). We used this information to isolate the full-
length coding sequences from chicken embryo mRNA. Based on
amino acid sequence similarities (50%) with the respective
human proteins, the proteins were assigned to 2 distinct groups
as chBP1 and chBP2 (Fig. 1A; supporting information (SI)
Fig. S1). Both protein families maintain the positioning of 8
cysteine residues, and the overall protein composition matches
with the conserved domain assigned to the FGF-BP gene family,
PFAM06473. It also is noteworthy that the FGF-binding domain
identified in the human BP1 protein (10) represents the most
conserved portion of the proteins when comparing human and
chick BPs (80% similarity; Fig. S1), supporting the notion of
a similar function. Also, the organization of the genomic locus
that contains BP1 and BP2 is conserved between human and
Gallus gallus with a single exon coding for the respective protein
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and a short genomic distance of 26 kb between the BP1 and
BP2 genes (Fig. 1B). We found shared synteny of BP1 and BP2
orthologues in the genomes of other vertebrates, including
Zebrafish and Xenopus. Interestingly, the rodent genome seems
to lack the BP2 locus, although we identified a distinct third
orthologue in the family, BP3, with shared synteny of human and
rodent orthologues (18).
In Vitro Function of chBP2.The BP1 proteins from different species
(human, mouse, rat, cow) have been characterized extensively
(see references in ref. 10), whereas human BP2 initially was
described by Ogawa et al. (19) as 37-kDa killer-specific secretory
protein (Ksp37) that is secreted by cytotoxic lymphocytes.
Therefore, we evaluated chBP2 in a set of experiments similar to
those that initially had revealed the mechanism of action and
function of BP1. After expression of chBP2 by transient trans-
fection, the protein is found in cell supernatants with an apparent
molecular mass of 30 kDa (Fig. 1C). Also, we found that the
secreted chBP2 protein binds to immobilized FGF2 (Fig. 1D).
For functional assays, FGF2-positive SW-13 cells were trans-
fected with a control or chBP2 expression vector. Expression of
chBP2 increased the induction of angiogenesis by these cells
when seeded onto a chick chorioallantoic membrane, induced
filopodia-like cellular extensions in attached cells, and stimu-
lated colony formation of the cells suspended in soft agar (Fig.
2A–E). A comparison with chBP1 shows similar binding to
immobilized FGF2 and induction of colony formation of trans-
fected SW-13 cells (Fig. S2). Therefore, chBP2 shares primary
structure and in vitro mechanism of action with the BP1 family
of proteins (8, 9, 20, 21), and the 2 families seem to be
functionally interchangeable.
Developmental Expression of chBP1 and chBP2. mRNA expression
during embryonic development was measured by quantitative
RT-PCR (qRT-PCR) and in situ hybridization. chBP2 expres-
sion is induced early in gestation after E5, peaking at E7/8 (Fig.
3C). Northern blotting confirmed this profile of chBP2 mRNA
regulation during chick development (data not shown). In
contrast to chBP2, the expression of chBP1 is induced at a later
time point, during mid-gestation, and peaks at E11/12 (Fig. 3C).
In situ hybridization at their respective expression peaks showed
that both chBP1 and chBP2 are highly expressed in the skin and
intestine and at intermediate levels in the lungs; little or no
expression was detectable in the heart and liver (Fig. 3 A and B;
Table S1). The expression pattern and timing of chBP1 parallels
that of murine BP1, which is induced during the last third of
gestation and shows the highest levels in the embryonic gut and
skin (22, 23).
Timed Knockdown of Peak Expression of chBPs. The rapid increase
of expression of chBP2 during the first 7 days of chick embryonic
development suggested a potentially crucial role during this
phase of development. To test this hypothesis, we initiated
siRNA-mediated knockdown of chBP2 expression starting on
Fig. 1. Characterization of chBP2. (A) Phylogenetic tree of known BP pro-
teins. (B) Organization of the human and chicken BP1 and BP2 genomic locus.
The ORFs (gray) are contained on single exons. The direction of transcription
and the distance between the ORFs is indicated. (C) Western blot for tagged
chBP2 protein harvested from the supernatants of transfected SW-13 cells. (D)
Binding of chBP2 to different concentrations of immobilized FGF2 relative to
a negative control (epidermal growth factor, EGF). Bound chBP2was quanti-
tated by ELISA. **, P  0.01. AU, absorption units.
Fig. 2. Effects of chBP2 expression in FGF2-positive SW-13 cells. (A, B)
Induction of angiogenesis in a chicken embryo chorioallantoic membrane
(CAM) assay. Cells were placed on a collagen gel matrix on the CAM, and
neoangiogenesis was scored. The arrowheads point to newly formed ves-
sels. (C, D) Induction of filopodia-like cellular extensions in attached cells
(38). Extensions were quantitated and are indicated by arrowheads. (E)
Colony formation in soft agar. Colonies 100 m were counted. Mock- or
chBP2-transfected SW-13 cells were compared in these assays. **, P 0.01.
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day E5. Day E3 embryos were removed from the eggshell, and
their growth was monitored in tissue culture dishes on top of
their yolk. This approach had been shown previously to provide
easy access to the embryos for introduction of transgene expres-
sion vectors by allantoic sac injection and allows continuous
monitoring for phenotypic effects (24). Here, we took advantage
of this approach using RNAi for timed knockdown of the
expression peaks of chBPs. siRNAs targeting either chBP1 or
chBP2 were administered by injection into the allantoic sac at
12-h intervals starting 24 h before the initiation of expression of
the respective chBP. For chBP2 targeting, embryos were micro-
injected with siRNA and harvested on E7 and E8. qRT-PCR
showed a significant knockdown of chBP2 expression by either
of 2 non-overlapping siRNAs (Fig. 4A). We reasoned that
chBP1-targeted siRNAs could serve as an additional negative
control in these experiments with chBP2, because chBP1 expres-
sion was at background levels during this early developmental
phase (see Fig. 3C). It is noteworthy that after initiation of chBP1
gene expression in later-stage embryos, chBP1 expression is
effectively knocked down by the chBP1-specific siRNAs. The
respective functional and phenotypic results are discussed below
(see Fig. 7).
Effect of chBP2 Knockdown on Embryo Survival and Phenotype.
siRNA-mediated knockdown of chBP2 expression resulted in
a significant increase in embryonic lethality compared with
embryos treated with control siRNA or chBP1-targeted
siRNA. One half of the embryos treated with chBP2 siRNA did
not survive the first 3 days, whereas none were lost in the
groups treated with control siRNA or chBP1 siRNA (Fig. 4B).
There was no difference in the survival rates of the embryos
treated with chBP1 or control siRNA, indicating that the
chBP1 siRNAs had no effect in these early-stage embryos that
had not yet initiated expression of chBP1 (Figs. 3C and 4B).
The most obvious phenotype in the chBP2 knockdown em-
bryos that survived the first few days of knockdown was a
reduction in ventral body wall closure resulting in an open
chest and abdominal wall (Fig. 5 D and F). These embryos also
displayed a red hue in the skin because of vascular leakage
(Fig. 5B) that was verified by extravasation of red cells in tissue
sections (not shown). Finally, a subtle delay in feather bud
formation was observed.
Effect of chBP2 Knockdown on HoxB Expression. Hox gene signaling
is a master pathway that could be impacted and lead to the severe
morphologic and lethal phenotype observed after the knock-
down of chBP2. Hox genes control anterior–posterior axis de-
velopment and are activated sequentially in response to signal
gradients (reviewed in ref. 25). Although anterior–posterior
signaling has been studied more extensively, Hox genes also play
a role in appropriate dorsoventral patterning that can control
ventral body wall closure; for example, overexpressing or exter-
nally adding FGFs to embryos can up-regulate posterior mem-
bers of theHox gene family (26–28). Although the control ofHox
gene expression is related to specific and consecutive somites,
the inability to demonstrate co-linearity with organ development
(e.g., in the thoracic region) suggests the involvement of addi-
tional control mechanisms (29, 30).
We focused onHoxB7 andHoxB8 because they are implicated
in the control of the abdominal and thoracic segments that
showed the most striking morphologic defects. Knockdown of
chBP2 was associated with a statistically significant 51% reduc-
tion of HoxB7 expression in E7 embryos and was still apparent,
although not statistically significant, at E8 (Fig. 6A). In contrast,
Fig. 3. Expression of chBPs during embryogenesis. (A, B) chBP2 mRNA
expression in skin at E7 by in situ hybridization. Table S1 shows results from
different tissues. (Scale bar, 0.1 mm.) (Inset) Magnification of indicated area.
(C) Time course of expression of chBP2 (@, Left Ordinate) and chBP1 (C, Right
Ordinate). mRNA levels were determined by qRT-PCR and are expressed
relative to GAPDH (n  3 or 4 embryos per time point).
Fig. 4. Effect of depletion of chBP2 on embryo viability. (A) siRNA knock-
down of chBP2 expression in vivo as measured by qRT-PCR and given relative
toGAPDH. The number of embryos in each group is indicated. A control siRNA
and 2 distinct siRNAs targeted to chBP2 were used (see Materials and Meth-
ods). **, P 0.01. (B) Survival of embryos injected with siRNAs to knock down
the expression peak of chBP2. Embryos injected every 12 h (Arrows) with
siRNAs specific for chBP2 (n  12) showed a reduced survival rate compared
with embryos treated with control siRNA (n  13; P  0.011) or with siRNA
specific for chBP1 (n 11; P 0.0054). (Control siRNA vs. chBP1-specific siRNA
treatment groups, P  0.05.)
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HoxB8 expression was not altered after the chBP2 knockdown
(Fig. 6B). It is noteworthy that the embryonic expression time
courses of HoxB7 and HoxB8 do not follow the patterns found
for either of the chBPs (not shown), and the knockdown of
chBP1 did not affect HoxB7 or HoxB8 expression (not shown).
Still, chBP2 seems to be required to maintain appropriateHoxB7
expression around E7, and this requirement may be sufficient to
explain the morphologic defect observed.
Potential Contribution of chBP2 to Hedgehog Signaling. Sonic hedge-
hog (Shh) controls the reach of signaling molecules crucial for
spatial and temporal induction of new cell types and morpho-
genesis. A positive feedback loop between Shh and FGF signal-
ing in developing limbs is well established with signal initiation
from the specialized cells of the apical ectodermal ridge and
signal maintenance by an FGF/Shh feedback loop (reviewed in
ref. 31). Close interaction of FGFs and Shh signaling also was
found in the development of other organ systems (32).
Thus, we measured Shh expression to assess whether FGF/
chBP2 participate in a feedback loop during this developmental
phase. Knockdown of chBP2 was associated with a statistically
significant 65% decrease in Shh expression at E7 that was still
apparent, although not statistically significant, at E8 (Fig. 6C).
The effect of chBP2 depletion on Shh seems to be specific to this
early developmental phase, because knockdown of the chBP1
expression peak at a later stage did not alter expression of Shh
(not shown).
MAPK Phosphatase 3 Expression as an Indicator of FGF Activity. The
dual-specificity MAPK phosphatase 3 (MKP3, also known as
DUSP6 or Pyst1) can negatively modulate FGF signaling. At
the same time, MKP3 expression levels in the chicken embryo
neuronal plate and limb buds are regulated by FGF and can
thus ref lect overall FGFR signaling (33, 34). This notion is
supported further by a gene expression survey of mouse
embryonic midbrain in which FGF signaling was disrupted by
tissue-selective knockout of FGFR1; MKP3 was one of the
response genes that was downregulated (35). In our studies, the
chBP2 knock-down reduced MKP3 expression levels by 50%
at E7/E8 (P 0.01 for chBP2 vs. control siRNA groups) (Fig.
6D), commensurate with reduced FGF activity in chick em-
bryos at this developmental stage. It is of note, however, that
knockdown of the later-stage chBP1 expression peak (dis-
cussed later) did have a detectable impact onMKP3 expression
(not shown). A likely explanation for this difference from
chBP2 is that the regulation of MKP3 expression by FGF
signaling is superseded by other control mechanisms at other
stages of development or growth.
Effect of chBP1 Knockdown on Embryo Viability and Phenotype.
Treatment of embryos with 2 chBP1-specific siRNAs reduced
the expression of the gene by 65% and resulted in a significant,
rapid onset of embryonic lethality within 3 days (Fig. 7). A
careful inspection, dissection, and histologic analysis of the
embryos did not reveal any visible organ malformation. Also, in
contrast to the chBP2 knockdown, no impact on HoxB7, HoxB8,
Shh, or MKP3 expression was seen in chicks treated with chBP1
siRNA (data not shown). Thus, the induction of expression of
both chBP1 and chBP2 is necessary for embryo viability, al-
though they govern distinct developmental phases. The reduced
embryo viability after chBP1 knockdown probably results from
subtle organ dysfunctions, because no obvious morphologic
alteration was detectable.
Conclusions
Here we show that expression of chBP1 and chBP2 are required
for embryonic development because knockdown of their respec-
Fig. 6. Impact of chBP2 knockdown on the expression of HoxB7 (A), HoxB8
(B), sonic hedgehog (SHH, C) and MKP3 (D). mRNA expression was measured
by qRT-PCR after treatment with control or chBP2-targeted siRNA. mRNA
levels are given relative to GAPDH. *, P  0.05.
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Fig. 5. Ventral wall closure in chicks treated with chBP2-specific siRNA
(Right) versus control siRNA (Left). Images (A–D) and H&E staining (E, F) of
chickembryosat E7.H,heart; L, liver. Thearrowheads indicate theedgesof the
ventral wall closure. (Scale bars, 1 mm in A–D and 0.1 mm in E and F).
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tive expression peaks reduced embryonic viability. The ventral
body wall defect observed after knockdown of chBP2 suggests a
crucial role in the maintenance of FGF signaling during dorso-
ventral patterning. Indeed, FGFs signal upstream of ventral
morphogens and can initiate dorsoventral patterning in early
Zebrafish embryos (36). Reduced expression of HoxB7 and Shh
after the knockdown of chBP2 is consistent with their partici-
pation in an FGF signaling feedback loop whose altered activity
is indicated by reduced MKP3 expression levels.
Secreted FGF BPs originally were thought to function as
‘‘angiogenic switch’’ molecules that are induced during malig-
nant progression (20). The present study reveals that BPs also
function as crucial regulators of embryonic development and
that chBP2 is involved in the control of HoxB7, Shh, and MKP3
expression, i.e., in the expression of genes whose pathways are
intertwined with FGF signaling. We propose that FGF signaling
during vertebrate development depends on the fine-tuning by
secreted FGF BPs .
Materials and Methods
Identification of chBP2. To identify a chicken homologue of human BP1, the
humanprotein sequence (accession#NP005121)was submitted to aTBLASTN
search at the National Center for Biotechnology Information (NCBI)/National
Institutes of Health. From this search we identified a chicken EST (accession
#AJ398183) that coded for a protein fragment homologous to the C terminus
of the human protein. The ORF of chBP2 then was identified using a 5 RACE
system (Life Technologies). For this identification, E17 chicken retina mRNA
was reverse-transcribed using the primer 5 CCA GCA GCT ACT TGC TTC AT 3.
A homopolymeric cytosine 3 tail was added followed by an initial PCR
performed with the primer pair 5 GGC CAC GCG TCG ACT AGT ACG GGI IGG
GII GGG IIG 3 and 5GGC ATG AGGGAG CTT TCT AAG T 3. A nested PCR then
was performed using the primer pair 5GGC CACGCG TCGACT AGT AC 3 and
5GGAAAGGAT GAC AGAGCA ATG G 3. The fragment then was sequenced
on both strands and was submitted to NCBI GenBank (accession number
AY164487). The ORF of chBP1 (derived from XM420773) was amplified from
E10 chicken embryo cDNAs using the primer pair 5CGA GCA AAA CAT GTG
GATT3and5GCACTTTTTGTCTTGCACCATG3. TheORFs of chBP1or chBP2
including a C-terminal V5 tag were inserted into pcDNA3 (Life Technologies),
sequence verified, and expressed in HEK293 or in SW-13 cells as described
previously for human BP1 (20). Tagged proteins in supernatants and in
cell lysates were detected using a commercially available anti-V5 antibody
(Invitrogen).
Cell Free Protein Binding Assays. FGF2 (at 0.1–10 g/mL in 0.2 mL of PBS) was
immobilized as a bait by overnight incubation at 4 °C in enzyme immunoassay
plates (Costar). Epidermal growth factor at the same concentrations served as
a negative control. Nonspecific binding sites were blocked by incubating in
1% BSA in PBS for 1 h at room temperature. V5-tagged BP proteins were
harvested from transiently transfected cells, added to wells coated with the
different baits, and incubated at room temperature for 1 h. The wells then
werewashed3 timeswithPBS-Tween. Bound chBPproteinwasquantitatedby
an anti-V5 HRP-conjugated antibody (Invitrogen), and subsequent develop-
ment was assessed by ELISA (Pierce).
Chicken Embryo Growth. E3 White Leghorn chicken embryos were obtained
fromCBT Farms. The studies did not involve the hatching of live birds and thus
were exempt from Institutional Animal Care and Use Committee approval.
Chicks were removed from their shells and transferred to 100-mm diameter,
20-mmdeep tissue culturedishes togetherwith substrate yolkandmaintained
at 38 °C at constant humidity. Blood flow visualized by stereomicroscopy was
used to monitor embryo viability.
Chorioallantoic Membrane Angiogenesis Assay. For the angiogenesis assays, a
1-mm3 gelatin sponge (Gelfoam, Upjohn) was placed at the periphery of the
chorioallantoic membrane on day E4. Five million SW-13 cells (mock or chBP2
transfected) were added to each sponge. The chorioallantoic membranes
were photographed 24 h later, and the degree of angiogenesis was scored in
a blinded fashion based on a 4-point scoring system (9).
siRNA Targeting. Two siRNAs obtained fromQiagenwere used to target chBP1
(targeted sequences: AAGGCATCTCCTAAAGGCAAAandAAACTTCAAGAT
ATATTCAA) and chBP2 (targeted sequences: GGAAACCTGCAGTGTTACCTC
and CTG CAT GTA CTG CAT TAT GTA). Luciferase-specific siRNA was used as a
control (targeted sequence: AAC GTA CGC GGA ATA CTT CGA).
RNA Detection. Chick embryos were harvested and homogenized in TRIzol
(Invitrogen). Total RNA was extracted using chloroform, precipitated, and
washed with ethanol. PolyA RNA was extracted from total RNA using Oli-
gotex kit (Qiagen). Gene expression was quantitated using RT-PCR Taqman
probes and the Platinum Quantitative RT-PCR Thermoscript One-Step system
(Invitrogen) for chBP1, chBP2, HoxB7, HoxB8, MKP3, and Shh. SYBR green
(Bio-Rad)wasused forGAPDHdetection.DNAprobesof knownconcentration
were used as additional internal standards. In situ hybridization was done as
described earlier (37) using embryo tissue samples fixed in 10% buffered
formalin and embedded in paraffin. Antisense and sense probes were gen-
erated by in vitro transcription with digoxigenin labeling using 2 separate
500-bp fragments specific for either chBP1or chBP2 that had been cloned into
the pGEM-T Easy Vector (Promega).
Data Analysis. Prism 5 (GraphPad Inc.) software was used for comparisons of
data sets by ANOVA or for survival analysis with p-values based on the
Gehan-Breslow algorithm.
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Fig. 7. Effects of chBP1 knockdown. (A) Expression of chBP1mRNA in chick
embryos at E9 and E10 treated with control siRNA or with 2 different siRNAs
targeted to chBP1 (see Materials and Methods). chBP1 mRNA was measured
byqRT-PCR, anddataaregiven relative toGAPDH.Thenumberof embryosper
group is indicated. **, P  0.01. (B) Survival of chicks treated with chBP1-
specific siRNA (n18) relative to control siRNA (n14).Arrows indicate siRNA
injections. *, P  0.017.
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